PRESS RELEASE published on 09/27/2024 at 11:24, 7 months 7 days ago HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF published on 09/23/2024 at 19:41, 7 months 11 days ago GenSight Biologics publie ses résultats financiers intermédiaires pour le premier semestre 2024 Résultats Financiers LUMEVOQ® Programme D'accès Anticipé Dépenses De Recherche Et Développement Gestion De Trésorerie
BRIEF published on 09/23/2024 at 19:41, 7 months 11 days ago GenSight Biologics Reports Interim Financial Results for H1 2024 Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
PRESS RELEASE published on 09/23/2024 at 19:36, 7 months 11 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie ses résultats financiers du premier semestre 2024 avec une réduction des dépenses opérationnelles de 60% et l'extension de son horizon de trésorerie. Nouveau Directeur Administratif et Financier nommé Résultats Financiers GenSight Biologics Directeur Administratif Et Financier Dépenses Opérationnelles Horizon De Trésorerie
PRESS RELEASE published on 09/23/2024 at 19:36, 7 months 11 days ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release
BRIEF published on 09/17/2024 at 14:45, 7 months 17 days ago Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
BRIEF published on 09/17/2024 at 14:45, 7 months 17 days ago Goldman Sachs vend ses actions GENSIGHT BIOLOGICS S.A. Euronext Paris Franchissement De Seuils Goldman Sachs Cession D'actions GenSight Biologics
PRESS RELEASE published on 09/17/2024 at 14:40, 7 months 17 days ago Franchissement de seuils Déclaration de franchissement de seuils par The Goldman Sachs Group, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Déclaration The Goldman Sachs Group Franchissement De Seuils GenSight Biologics
BRIEF published on 07/23/2024 at 07:35, 9 months 13 days ago GenSight Biologics Reports Financial Position and Business Progress Gene Therapy Financial Update GenSight Biologics LUMEVOQ Early Access Program
BRIEF published on 07/23/2024 at 07:35, 9 months 13 days ago GenSight Biologics présente sa situation financière et ses progrès commerciaux Thérapie Génique Mise À Jour Financière Produits Biologiques GenSight LUMEVOQ Programme D'accès Anticipé
Published on 05/05/2025 at 08:00, 10 minutes ago Formation Metals Unlocks Copper-Zinc Potential at the N2 Gold Deposit with Insights from Revaluation of Historic Drill Core
Published on 05/05/2025 at 02:30, 5 hours 40 minutes ago Optimised Scoping Study Accelerates Tunkillia PFS Programs
Published on 05/03/2025 at 03:40, 2 days 4 hours ago Snipp Interactive Announces Delay in Filing Audited Fiscal 2024 Financial Statements
Published on 05/03/2025 at 03:00, 2 days 5 hours ago Vision Marine Technologies Inc. Announces Postponement of Annual Meeting of Shareholders
Published on 05/03/2025 at 02:06, 2 days 6 hours ago Battery X Metals Achieves Pivotal Milestone with Delivery of Next-Generation Lithium-Ion Battery Rebalancing Machine and Announces Exclusive Live Reveal Event
Published on 05/05/2025 at 08:02, 8 minutes ago PFISTERER Holding SE announces price range and offers structure for planned IPO
Published on 05/05/2025 at 07:35, 35 minutes ago Circus SE and REWE Region West launch exclusive national pilot partnership for the integration of the CA-1 robot
Published on 05/05/2025 at 07:30, 40 minutes ago Masterflex SE expands production capacity in aviation business – new plant planned in Morocco
Published on 05/05/2025 at 07:00, 1 hour 10 minutes ago Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report
Published on 05/05/2025 at 07:30, 40 minutes ago Gimv geht Partnerschaft mit Ambulantis ein und unterstützt die Wachstumsambitionen des Unternehmens
Published on 05/05/2025 at 07:30, 40 minutes ago Gimv investeert in Ambulantis om de groeiambities van het bedrijf te ondersteunen
Published on 05/05/2025 at 07:30, 40 minutes ago Gimv partners with Ambulantis to support the company's growth ambitions
Published on 05/05/2025 at 07:30, 40 minutes ago Gimv partners with Ambulantis to support the company's growth ambitions
Published on 05/04/2025 at 22:39, 9 hours 31 minutes ago Déclaration des transactions sur actions propres réalisées du 22 au 25 avril 2025